Thursday September 6, 7:31 pm Eastern Time
Press Release
SOURCE: Telik, Inc.
Telik Scientists to Present At CaP CURE Scientific Retreat
SOUTH SAN FRANCISCO, Calif.--(BW HealthWire)--Sept. 6, 2001-- Telik, Inc. (Nasdaq:TELK - news) announced the presentation of data on TRAP chemogenomics technology and the lead oncology development candidate TLK286 at the Eighth Annual Scientific Retreat sponsored by CaP CURE, the world's largest private source of prostate cancer research funding. The meeting brings together leading researchers from around the world to discuss recent findings and potential new approaches to the treatment of prostate cancer.
Telik scientists will present the company's TRAP technology that uses proprietary computational methods to rapidly and efficiently identify small molecule drug leads for a wide array of pharmaceutical targets. Telik used TRAP to help identify TLK286, a novel tumor-activated anti-cancer drug candidate currently in Phase 2 clinical trials for the treatment of resistant cancers. TRAP was also used to identify small molecules that inhibit the activity of insulin-like growth factor-1 (IGF-1), a potential target for prostate cancer therapy. Another approach to cancer therapy explored by Telik, in collaboration with Genaissance Pharmaceuticals, Inc., involved the use of TRAP to identify novel estrogen receptor modulators with specificity for estrogen receptor subtypes. Compounds emerging from this program may provide new approaches to the treatment and/or prevention of various hormonally responsive cancers, including prostate cancer.
Telik, Inc. of South San Francisco, CA is a biopharmaceutical company working to discover, develop and commercialize small molecule drugs to treat serious diseases for which there is significant demand for new therapies. The company's most advanced drug development programs include: TLK286, a tumor activated drug candidate for the treatment of major cancers that are resistant to standard treatments, currently in Phase 2 studies in colorectal, ovarian and non-small cell lung cancers; TLK199, a candidate for the treatment of low white blood cell levels that occur as a toxic side effect of cancer therapy as well as in other blood diseases such as myelodysplastic syndrome, a preleukemic condition; and a family of orally active insulin receptor activators for Type 2 diabetes. Telik's product candidates were discovered using its proprietary technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
snip |
